石藥(01093.HK)附屬抗凝藥獲國家藥監局頒發藥品註冊批件
石藥集團(01093.HK)公布,附屬公司石藥集團歐意藥業開發的「利伐沙班片(10mg)」已獲得中國國家藥品監督管理局頒發藥品註冊批件,為國內該品種第二家獲批並視同通過質量及療效一致性評價的仿製藥。利伐沙班為抗凝藥,適用於擇期髖關節或膝關節置換手術成年患者,以預防靜脈血栓形成;治療成人深靜脈血栓和肺栓塞,降低初始治療6個月後復發的風險;具有一種或多種危險因素(如充血性心力衰竭、高血壓、75歲或以上、糖尿病、卒中或短暫性腦缺血發作病史)的非瓣膜性房顫成年患者,降低卒中和全身性栓塞的風險。該產品為一種口服直接抑制Xa因子的抗凝藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.